吉西他滨联合顺铂治疗晚期非小细胞肺癌  

Combined chemotherapy of gemcitabine and cisplatin in the treatment of advanced non-small cell lung cancer

作　　者：鲁军[1] 刘莉萍[1] 李晶[1] 杨小红[1] 

机构地区：[1]湖南省肿瘤医院内三科,湖南长沙410013

出　　处：《世界肿瘤杂志》2006年第4期267-268,共2页Tumour Journal of the World

摘　　要：目的观察吉西他滨联合顺铂治疗晚期非小细胞肺癌的疗效和安全性．方法吉西他滨联合顺铂治疗37例初治的晚期非小细胞肺癌病人。吉西他滨1000mg／m^2，静脉滴注，d1，d8;顺铂30mg／m^2，静脉滴注，d1～3，21d为一周期．每例病人治疗24周期。结果全组37例均可评价疗效，完全缓解者占2．7％（1／37），部分缓解者占45．9％（17／37），稳定者占40．6％（15／37），进展者占10．8％（4／37），有效率（RR）为48．6％。中位进展时间（TTP）为6．5mo，中位生存期为10．7mo，1年生存率为43．2％（16137）。主要不良反应为血液学毒性，Ⅲ～Ⅳ度白细胞下降者占24.3％（9／37），Ⅲ度血小板下降者占10．8％（4／37），无Ⅳ度下降者。恶心呕吐发生率为78.4％，仅2例为毒性反应Ⅲ度。结论吉西他滨联合顺铂治疗晚期非小细胞肺癌有较好的疗效，病人不良反应可以耐受。Objective To evaluate the efficacy and safety of gemcitabine and cisplatin （GP） combination in advanced non-small cell lung cancer （NSCLC）. Methods Thirty-seven patients with advanced NSCLC were enrolled into the study. The GP regimen consisted of gemcitabine 1000mg/m^2 on day 1, 8 and cisplatin 30mg/m^2 on days 1 , 2, and 3. GP was given every 21 days. Each patient received at least two cycles. Results In 37 patients, responses included one complete remissions and seventeen partial remissions. Overall response rate was 48.6%（18/37）, 15 patients had stable disease and four had progressive disease. Median time to progression and overall survival were 6.5 and 10.7 months, respectively. The 1-year survival rate was 43.2%.The main toxicity was hematological toxicity. Grade Ⅲ-Ⅳ leukopenia was seen in nine patients （24.3%） and no febrile neutropenia, grade Ⅲ thrombocytopenia was seen in four patients （10.8%）. Nausea or vomiting was seen in 29 patients （78.4%）, including 2 patients with grade Ⅲ. Condusions the GP combination seems highly active and tolerable in patients with advanced NSCLC.

关 键 词：吉西他滨 顺铂 非小细胞肺癌 化疗 

分 类 号：R734.2[医药卫生—肿瘤] R730.53[医药卫生—临床医学]